{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T10:01:19Z","timestamp":1773568879025,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007366","name":"Fondazione Italiana Sclerosi Multipla","doi-asserted-by":"publisher","award":["2020\/S\/5"],"award-info":[{"award-number":["2020\/S\/5"]}],"id":[{"id":"10.13039\/100007366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2013-02357497"],"award-info":[{"award-number":["RF-2013-02357497"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.msard.2022.104176","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T02:33:24Z","timestamp":1663122804000},"page":"104176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3819-9409","authenticated-orcid":false,"given":"Paola","family":"Valentino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Malucchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Martire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia Irene","family":"Bava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Alfonso","family":"Capobianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Bertolotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.104176_bib0001","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000555","article-title":"Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS","volume":"6","author":"Akg\u00fcn","year":"2019","journal-title":"Neurol. Neuroimmunol. NeuroInflammat."},{"key":"10.1016\/j.msard.2022.104176_bib0002","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.msard.2022.104176_bib0003","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1002\/acn3.51234","article-title":"Blood neurofilament light: a critical review of its application to neurologic disease","volume":"7","author":"Barro","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2022.104176_bib0004","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2022.104176_bib0005","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1093\/brain\/awab241","article-title":"The potential of serum neurofilament as biomarker for multiple sclerosis","volume":"144","author":"Bittner","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.msard.2022.104176_bib0006","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.104176_bib0007","doi-asserted-by":"crossref","first-page":"E1898","DOI":"10.1212\/WNL.0000000000012752","article-title":"Serum neurofilament light association with progression in natalizumab-treated patients with relapsing-remitting multiple sclerosis","volume":"97","author":"Bridel","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104176_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211042458","article-title":"No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)","volume":"14","author":"Butzkueven","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2022.104176_bib0009","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1002\/acn3.51471","article-title":"Measuring treatment response to advance precision medicine for multiple sclerosis","volume":"8","author":"Calabresi","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2022.104176_bib0010","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ana.25437","article-title":"Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients","volume":"85","author":"Dalla Costa","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2022.104176_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117385","article-title":"MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study","volume":"424","author":"De Mercanti","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2022.104176_bib0012","doi-asserted-by":"crossref","first-page":"e1201","DOI":"10.1212\/WNL.0000000000009097","article-title":"Blood neurofilament light levels segregate treatment effects in multiple sclerosis","volume":"94","author":"Delcoigne","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104176_bib0013","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2022.104176_bib0014","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001003","article-title":"Serum neurofilament levels and PML risk in patients with multiple sclerosis treated with natalizumab","volume":"8","author":"Fissolo","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflammat."},{"key":"10.1016\/j.msard.2022.104176_bib0015","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.94.15_supplement.2013","article-title":"Serum Neurofilament Light (sNfL) levels in patients with Relapsing-remitting Multiple Sclerosis (RRMS) Switching from Natalizumab Every-4-week (Q4W) dosing to extended interval dosing (EID) (2013)","volume":"94","author":"Foley","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104176_bib0016","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.msard.2022.104176_bib0017","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/00365513.2020.1730434","article-title":"Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults","volume":"80","author":"Hviid","year":"2020","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"10.1016\/j.msard.2022.104176_bib0018","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/1352458519840757","article-title":"Longitudinal analysis of serum neurofilament light chain: a potential therapeutic monitoring biomarker for multiple sclerosis","volume":"26","author":"Hyun","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2022.104176_bib0019","doi-asserted-by":"crossref","unstructured":"Johnsson, M., Farman, H.H., Blennow, K., Zetterberg, H., Malmestr\u00f6m, C., Axelsson, M., Lycke, J., 2022. No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab 1-11. 10.1177\/13524585221108080.","DOI":"10.1177\/13524585221108080"},{"key":"10.1016\/j.msard.2022.104176_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-14612-6","article-title":"Serum neurofilament light levels in normal aging and their association with morphologic brain changes","volume":"11","author":"Khalil","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.msard.2022.104176_bib0021","doi-asserted-by":"crossref","first-page":"P706","DOI":"10.1016\/j.jalz.2018.06.783","article-title":"P2-098: comparison of two platforms quantitating Fg\/Ml neurological biomarkers using single molecule arrays and digital Elisa: the benchtop reader Sr-XTM and the fully automated analyzer Hd-1TM","volume":"14","author":"Lambert","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.msard.2022.104176_bib0022","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ana.25523","article-title":"Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy","volume":"86","author":"Loonstra","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2022.104176_bib0023","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/acn3.50972","article-title":"Confounding effect of blood volume and body mass index on blood neurofilament light chain levels","volume":"7","author":"Manouchehrinia","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2022.104176_bib0024","first-page":"43","article-title":"BB-cresm: a structured institutional biobank for quality research in multiple sclerosis_LB1245","volume":"26","author":"Marnetto","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2022.104176_bib0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2217\/nmt-2021-0038","article-title":"Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis","volume":"12","author":"Moccia","year":"2022","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.msard.2022.104176_bib0026","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104176_bib0027","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104176_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103480","article-title":"No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS","volume":"58","author":"Ryerson","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104176_bib0029","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/1352458519901272","article-title":"Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis","volume":"27","author":"Srpova","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2022.104176_bib0030","doi-asserted-by":"crossref","unstructured":"Teunissen, C.E., Petzold, A., Bennett, J.L., Berven, F.S., Brundin, L., Comabella, M., Franciotta, D., Frederiksen, J.L., Fleming, J.O., Furlan, R., Hintzen, R.Q., Hughes, S.G., Johnson, M.H., Krasulova, D.E., Kuhle, J., Magnone, M.C., Rajda, C., Rejdak, K., Schmidt, H.K., Van Pesch, V., Waubant, E., Wolf, C., Giovannoni, G., Hemmer, B., Tumani, H., Deisenhammer, F., 2009. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking Supplemental data at www.neurology.org VIEWS & REVIEWS.","DOI":"10.1212\/WNL.0b013e3181c47cc2"},{"key":"10.1016\/j.msard.2022.104176_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-67504-6","article-title":"Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis","volume":"10","author":"Thebault","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2022.104176_bib0032","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2022.104176_bib0033","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000714","article-title":"Monitoring of radiologic disease activity by serum neurofilaments in MS","volume":"7","author":"Uher","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflammat."},{"key":"10.1016\/j.msard.2022.104176_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103090","article-title":"Serum neurofilament light chain levels in healthy individuals: a proposal of cut-off values for use in multiple sclerosis clinical practice","volume":"54","author":"Valentino","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104176_bib0035","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1212\/WNL.0000000000009995","article-title":"Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial","volume":"95","author":"van Kempen","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104176_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.00338","article-title":"Neurofilament light chain as a biomarker in multiple sclerosis","author":"Varhaug","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2022.104176_bib0037","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"2021 MAGNIMS\u2013CMSC\u2013NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","volume":"20","author":"Wattjes","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2022.104176_bib0038","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.msard.2018.06.015","article-title":"Efficacy and safety of natalizumab extended interval dosing","volume":"24","author":"Yamout","year":"2018","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822006812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822006812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:07:59Z","timestamp":1761901679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822006812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":38,"alternative-id":["S2211034822006812"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104176","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104176"}}